



June 2008

## Ethypharm in Philadelphia

### The DDS Group confirms its implantation on the American Market

Ethypharm sets up in the United States and announces the opening of a commercial office in Philadelphia (Pennsylvania) as from June, 1st 2008. Located in the city business district, the Company thus confirms its intention for further expansion in the United States of America.

« The development of our commercial activities added to several projects reaching filing stage represent for us a great opportunity to start building a stronger presence in USA, » declared Hafid Touam, Chief Executive Officer for Ethypharm North America.

“Three products developed by Ethypharm French and Canadian R&D teams were recently licensed to major pharmaceutical players, and will be filed with the American Food and Drug Administration within the next few weeks », he added.

Ethypharm current pipeline includes in excess of 20 products at different stage of development. Most of them target the American Market. Four additional products will be submitted to the FDA within the next 12 months; two of them will be filed under Ethypharm's own name.

In the next few years, Ethypharm will continue to seek collaboration in product development with new partners, mainly in the field of Orally Disintegrating Tablets, using its proprietary Flashtab® technology (Taste Masked ODT, Bi Layer ODT, SR ODT) and Oral Modified Release Technology (Nanonization, Transmucosal, Tablets, Pellets).

Many products using Ethypharm Flashtab® technology are already marketed in different Territories throughout the world i.e. prednisolone, tramadol ODT, ibuprofen ODT, tramadol APAP ODT fix dose combination, as well as ondansetron and mirtazapine ODT, both commercialized in the US by one of the generic market leader.

Ethypharm is also developing products using its Sublingual Tablet Technology. One of its most recent successes is linked to the successful launch in France of a sublingual tablet of buprenorphine by its two marketing partners, Mylan and Colbalt/Arrow.

Within this context, a new Business Development Director, a Regulatory Affairs Coordinator as well as a Senior Project Manager will shortly be joining and strengthening the Ethypharm USA team.

Ethypharm's expansion in the United States will have a significant impact in the company's results and in its ability to reach its financial objectives. « The greater Philadelphia area is one of America's leading pharmaceuticals and biotechnology centres with a majority of the world's largest pharmaceutical companies maintaining a presence in the region. The opening of our new office in Philadelphia is the first step of a strong investment in the future by Ethypharm and underscores our commitment to the U.S. market, » concluded Alexandre Williams, V.P Business Development.

Ethypharm  
194 Bureaux de la Colline  
92 213 Saint-Cloud, France

Tel: +33 1 41 12 17 20  
[www.ethypharm.com](http://www.ethypharm.com)